ArticleBMC cancer2015

Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study.

Mélodie Dell'Ova et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.